drugset / Trial / NCT00038961

A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

NCT00038961

Phase 3 Completed 1309 enrolled GlaxoSmithKline Sanofi · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a multicentre, randomized, double-blind, placebo controlled study. During this study all the patients will receive background venous thromboembolism (VTE) mechanical prophylaxis with intermittent pneumatic compression (IPC).

Timeline

Start
2001-11
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fondaparinux Other / unclassified 2.5 mg Subcutaneous